Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis

BACKGROUND: Type 2 diabetes (T2D) patients face increased risk of heart failure (HF) as they age. Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) have demonstrated effectiveness in reducing HF hospitalizations in patients with T2D and HF with reduced ejection fraction (HFrEF). Diabetes guideline...

Descripción completa

Detalles Bibliográficos
Autores principales: Glover, Sarah, Borrego, Matthew E, Ray, Gretchen M, Roberts, Melissa H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278724/
https://www.ncbi.nlm.nih.gov/pubmed/35845354
http://dx.doi.org/10.2147/CEOR.S361886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278724/
https://www.ncbi.nlm.nih.gov/pubmed/35845354
http://dx.doi.org/10.2147/CEOR.S361886

Ejemplares similares